Table 1.
Demographics, metformin dosing and area under the concentration-time curve for subjects with gestational diabetes, non-pregnant subjects with type 2 diabetes mellitus and healthy pregnant subjects
| GDM | T2DM | HP | |
|---|---|---|---|
| n | 25 | 12 | 28 |
| Age SD1 (years) | 31 ± 5 (22 to 39) |
33 ± 7 (23 to 45) |
25 ± 5 (18 to 38) |
| Height SD1 (cm) | 163 ± 6 (155 to 179) |
160 ± 8 (147 to 175) |
162 ± 8 (147 to 178) |
| Body weight SD1 (kg) | 90 ± 20 (70 to 100) |
100 ± 30 (60 to 100) |
80 ± 10 (50 to 109) |
| BMI Pre-pregnancy (kg/m2) | 31 ± 6 (21 to 43) |
36 ± 7 (24 to 46) |
27 ± 5 (20 to 40) |
| GA, SD1 (weeks) | 31 ± 2 (20 to 33) |
NA | 30 ± 1 (28 to 33) |
| GA, SD2 (weeks) | 35 ± 1 (32 to 38) |
NA | 36 ± 1 (34 to 38) |
| Metformin dose SD2 (mg/day) | 1,400 ± 500 (1,000 to 2,000) |
800 ± 200 (500 to 1,000) |
NA |
| Metformin AUC (μg•hr/mL) | 11 ± 4 | 12 ± 3 | NA |
| White | 80% | 75% | 82% |
| Black | 16% | 25% | 18% |
| Asian | 4% | 0% | 0% |
| Hispanic/Latina | 36% | 67% | 32% |
| Baseline C-peptide AUC (pmol•hr/L) | 12,000 ± 4000 | 8000 ± 4000 | 9000 ± 3000 |
| Baseline glucose AUC (mg•hr/L) | 500 ± 70 | 1000 ± 400 | 380 ± 40 |
| Baseline insulin AUC (uU•hr /mL) | 300 ± 100 | 200 ± 200 | 190 ± 80 |
BMI = Body Mass Index, GA = gestational age, GDM = gestational diabetes mellitus, T2DM = type 2 diabetes mellitus, HP = healthy pregnant subjects, SD1 = study day 1, SD2 = study day 2. Results reported as mean ± standard deviation.